Consistently it is noteworthy that a pharmacological treatment of high-salt fed SHRSP with a novel class of drugs (the type 1 angiotensin II receptor and neprilysin (NEP) inhibitor, ARNi) led to a dramatic reduction of stroke occurrence along with a significant increase of ANP levels in both circulation and brain tissue [58]. The gene discussed is NPPA; the disease is stroke disorder.